Rasmussen, Lucy;
Morris, Shannon;
Wolitz, Richard;
Dowling, Anna;
Fessell, Jeffrey;
Holodniy, Mark;
Merigan, Thomas C.
Deficiency in Antibody Response to Human Cytomegalovirus Glycoprotein gH in Human Immunodeficiency Virus-Infected Patients at Risk for Cytomegalovirus Retinitis
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Deficiency in Antibody Response to Human Cytomegalovirus Glycoprotein gH in Human Immunodeficiency Virus-Infected Patients at Risk for Cytomegalovirus Retinitis
Contributor:
Rasmussen, Lucy;
Morris, Shannon;
Wolitz, Richard;
Dowling, Anna;
Fessell, Jeffrey;
Holodniy, Mark;
Merigan, Thomas C.
Published:
University of Chicago Press, 1994
Published in:
The Journal of Infectious Diseases, 170 (1994) 3, Seite 673-677
Description:
Human immunodeficiency virus (HIV)-infected patients at risk for symptomatic human cytomegalovirus (CMV) infection were studied for serum antibody to CMV glycoproteins gH and gB. Antibody titers to gB in HIV-seropositive patients, irrespective of CD4 cell counts or presence of CMV retinitis, were significantly higher than titers in HIV-seronegative, CMV-seropositive patients but were comparable to titers detected in HIV-seronegative patients with CMV mononucleosis. In contrast, antibody to gH was rarely detected in HIV-seropositive patients with CD4 cell counts >100/mm³ compared with patients with counts >100/mm³. The inability to detect gH antibody at a time of high risk for symptomatic CMV retinitis suggests that immune intervention with either gH-specific vaccine or passive immunotherapy may benefit HIV-infected persons at risk for symptomatic CMV disease.